Adamis Vaccine Technology Granted a Patent in Europe

Adamis Vaccine Technology Granted a Patent in Europe

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB:ADMP), today announced the technology which constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, was recently granted a patent in Europe. A patent entitled "Somatic transgene immunization and related methods" has been issued. Although genetic vaccines (DNA) have been used, there remains a need to develop more effective methods to exploit their ability to induce a reproducible immune response. The present invention satisfies this need and provides related advantages as well. The issued claims offer broad protection of a technology platform developed by Dr. Maurizio Zanetti, Professor of Medicine and Director of the Laboratory of Immunology at the UC San Diego Moores Cancer Center.

The technology platform provides a method for delivering a nucleic acid molecule such as a DNA vaccine into B cells (a cell of the immune system); this method is termed somatic transgene immunization or STI. It allows for the development of specific vaccines for the treatment of various tumors and infectious diseases. The technology uses the patient's own B cells for antigen production, as well as for antigen presentation. STI introduces into a host the "blueprint" for vaccine molecules in a way that mimics viral infections without the infectious threat. The introduction of functional genes into B cells of immunocompetent adults is a simple and elegant way to mimic natural infection and produce protective immunity. STI activates CD4 and CD8 T cells (cells of the immune system), as well as inducing normal T cell memory. The recently issued claims protect the use of STI for the treatment of any disease indication, including viral and bacterial infections (such as e.g. influenza, hepatitis B and C, human papilloma virus, etc.) and also tumors, such as cancer of the prostate, colon, lung, breast, melanoma, and others.

Adamis previously announced that a Phase 1 study was completed utilizing STI in its TeloB-VAX technology in castrate resistant prostate cancer (CRPC) patients. The study demonstrated this vaccine to be safe, non-toxic and immunogenic. It was shown that the vaccine induced the production of T cells that were capable of killing prostate cancer cells. Adamis has recently contracted for the manufacture of additional plasmid in preparation for expanding the clinical vaccine studies in prostate cancer patients. Adamis intends to conduct a Phase 2 study in castrate resistant prostate cancer patients. Please see Adamis' website for a short animated video describing and explaining the TeloB-VAX process and procedure (www.adamispharma.com).

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations or future financial performance, including, but not limited to the following statements: the company's beliefs concerning the safety and effectiveness of the compounds and drug product candidates described in this press release; the results of any future clinical trials that the company may conduct relating to the licensed compounds; the ability to fund future product development; future revenues expected from any of the licensed compounds, assuming that they are developed and approved for marketing by the FDA and other regulatory authorities; and the intellectual property protection that may be afforded by any patents or patent applications relating to the licensed technology. Statements in this press release concerning future milestone events depend on several factors beyond the company's control, including receipt of adequate funding to support these activities. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis' actual results to be materially different from these forward-looking statements. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis' filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Adamis expressly disclaims any intent to update any forward-looking statements.

Contacts

Capital Group Communications, Inc.
Mark Gundy, 415-332-7200
[email protected]

 

 

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.